{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fraser-Bell S"],"funding":["Allergan"],"pagination":["72-78"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9763166"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["107(1)"],"pubmed_abstract":["<h4>Aim</h4>To evaluate the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naïve diabetic macular oedema (DME).<h4>Methods</h4>The open-label, prospective, phase 4, real-world study included pseudophakic eyes and phakic eyes scheduled for cataract surgery that were treatment-naïve or non-responsive to antivascular endothelial growth factors. No eyes were excluded based on baseline best-corrected visual acuity (BCVA) or central subfield retinal thickness (CRT). After the initial DEX injection at the baseline visit, reinjection was permitted at ≥16-week intervals. Week-16 and week-52 visits were mandatory. Primary endpoints were changes in mean BCVA and CRT from baseline to 52 weeks.<h4>Resul"],"journal":["The British journal of ophthalmology"],"pubmed_title":["Dexamethasone intravitreal implant in treatment-naive diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study."],"pmcid":["PMC9763166"],"funding_grant_id":["Not applicable"],"pubmed_authors":["Kang HK","Simonyi S","Mitchell P","Arnold JJ","Tainton J","Fraser-Bell S"],"additional_accession":[]},"is_claimable":false,"name":"Dexamethasone intravitreal implant in treatment-naive diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study.","description":"<h4>Aim</h4>To evaluate the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naïve diabetic macular oedema (DME).<h4>Methods</h4>The open-label, prospective, phase 4, real-world study included pseudophakic eyes and phakic eyes scheduled for cataract surgery that were treatment-naïve or non-responsive to antivascular endothelial growth factors. No eyes were excluded based on baseline best-corrected visual acuity (BCVA) or central subfield retinal thickness (CRT). After the initial DEX injection at the baseline visit, reinjection was permitted at ≥16-week intervals. Week-16 and week-52 visits were mandatory. Primary endpoints were changes in mean BCVA and CRT from baseline to 52 weeks.<h4>Resul","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-06-08T06:46:13.991Z","creation":"2026-06-08T03:13:48.33Z"},"accession":"S-EPMC9763166","cross_references":{"pubmed":["34433549"],"doi":["10.1136/bjophthalmol-2021-319070"]}}